For decades, depression was viewed primarily as a disorder of brain chemistry. While neurotransmitters such as serotonin, dopamine, and glutamate remain critically important, modern neuroscience increasingly recognizes that the immune system also communicates continuously with the brain. A landmark study published in Molecular Psychiatry in July 2026 adds to this growing body of evidence by demonstrating that ketamine and several psychedelic compounds may converge on remarkably similar downstream biological pathways despite acting on very different receptors.
The investigators examined intravenous ketamine, psilocybin, LSD, and hydroxynorketamine using multiple complementary techniques including stem-cell-derived neurons, cerebrospinal fluid protein analysis, blood gene expression, immune signaling molecules, and advanced brain imaging. Rather than focusing only on where each drug begins its action, the researchers asked a more clinically meaningful question: do these treatments ultimately produce a common healing response?
Their answer was yes. Across multiple experimental systems the investigators identified shared neuroimmune signaling centered on immune messengers including IL-15, IL-7, and MCP-1. Although these names sound technical, they represent communication molecules used by immune cells and the nervous system. The findings suggest that rapid-acting antidepressants may help restore balance between the brain and immune system while promoting the neuroplasticity that is believed to underlie recovery from depression.
Why this matters
Treatment-resistant depression remains one of the greatest challenges in psychiatry. Many patients have tried numerous antidepressants, psychotherapy, lifestyle interventions, and other treatments before considering ketamine. Current clinical practice largely relies on observation to determine who will respond. This study moves the field toward identifying measurable biological markers that may eventually predict treatment response before treatment even begins.
The investigators demonstrated that ketamine responders showed distinct immune signatures compared with nonresponders. They also found that specific cytokine ratios predicted both response and nonresponse, raising the possibility that future laboratory testing could help personalize therapy.
Importantly, this research does not suggest that depression is simply an inflammatory disease. Instead, it supports the concept that depression involves complex interactions among immune signaling, neural plasticity, metabolism, and functional brain networks. Ketamine appears to influence many of these systems simultaneously rather than acting through a single mechanism.
The study also reinforces an increasingly important concept: ketamine and psychedelic medicines may share common downstream biology despite producing very different subjective experiences. Although ketamine primarily affects NMDA receptors while psychedelics primarily stimulate serotonin 5-HT2A receptors, both ultimately appear to engage pathways involved in neuroplasticity and immune regulation.
What does this mean for patients?
Patients should understand that these biomarkers are not yet ready for routine clinical use. No physician should currently order IL-7 or IL-15 testing to determine whether ketamine will work because these findings require replication in larger populations. Nevertheless, this represents exactly the type of translational research that advances the field from trial-and-error medicine toward precision psychiatry.
The study also helps explain why ketamine often produces improvements that extend beyond mood alone. Many patients report better cognitive flexibility, reduced rumination, increased motivation, and improved emotional resilience. These changes may reflect widespread remodeling of brain networks rather than simply increasing one neurotransmitter.
What this means for patients at Innerbloom Ketamine Therapy
At Innerbloom Ketamine Therapy, our treatment philosophy has always emphasized individualized care rather than a one-size-fits-all approach. Studies like this reinforce that treatment-resistant depression is biologically complex and that ketamine’s benefits likely extend far beyond temporary symptom reduction.
While this research will not immediately change how we administer IV ketamine, it points toward a future in which physicians may combine clinical assessment with biological markers to personalize treatment selection, optimize dosing strategies, predict who is most likely to benefit, and identify patients who may require additional therapies.
Future studies may also help explain why some individuals respond rapidly, why others require additional treatments, and why maintenance schedules differ substantially between patients. Ultimately, precision biomarkers could allow clinicians to make better-informed decisions while reducing unnecessary delays in finding effective treatment.
Our prediction is that the next decade of ketamine research will increasingly focus on precision medicine. Instead of asking simply whether ketamine works, researchers will ask which patients respond best, why they respond, and how treatment protocols can be individualized. The present study represents an important step toward that future.
Final thoughts
This publication represents one of the most comprehensive mechanistic studies of rapid-acting antidepressants to date. By integrating genetics, immune biology, brain imaging, and clinical outcomes, it provides compelling evidence that ketamine and psychedelics converge on shared biological pathways despite different pharmacologic starting points.
For patients living with treatment-resistant depression, that message is encouraging. Each new discovery brings psychiatry closer to understanding not only how ketamine works but also how to deliver the right treatment to the right patient at the right time.
About the Author
Dr. Rivas is a ketamine specialist and board-certified acute care and trauma surgeon with over 12 years of experience in ketamine administration. Before founding Innerbloom Ketamine Therapy in 2022, Dr. Rivas served on the frontlines of emergency and trauma medicine in Santa Maria, CA, and Austin, TX. Dr. Rivas applies his extensive medical expertise to provide safe, evidence-based ketamine treatments for mood disorders, including depression, anxiety, PTSD, and chronic pain. His passion lies in helping patients find relief and rediscover hope through personalized, compassionate care.
Newy: Bridging the Gap Between Ketamine Treatment and Everyday Wellness
A supplement formulated by Dr. Rivas for enhanced brain and mood support. The formula pairs especially well with ketamine therapy by helping extend and enhance the neuroplasticity effects. That said, the ingredients are equally effective on their own, so it’s a supportive option whether or not someone is undergoing ketamine treatment. Learn more about how Newy supports cognitive function detoxification and cellular repair.
Medical Disclaimer
All content on this website, including but not limited to this article, blog posts, testimonials, and FAQs, is not medical advice and should not be considered as such. This website cannot diagnose or treat any medical condition. Only a licensed medical professional who is familiar with you and your medical history can provide medical advice, diagnosis, or treatment.
The information provided here is for educational and informational purposes only. It is not intended to replace a consultation with a qualified healthcare provider. If you are experiencing symptoms of depression or any mental health condition, please consult with a licensed mental health professional or your primary care physician.
If you are in crisis or experiencing suicidal thoughts, please call the 988 Suicide and Crisis Lifeline (call or text 988) or go to your nearest emergency room immediately.
Innerbloom Ketamine Therapy cannot be held responsible or liable for any actions taken by those who access our website or rely on its content. Please refer to our Terms & Conditions for more information.
Ready to explore whether ketamine therapy is right for you? Contact Innerbloom Ketamine Therapy at (805) 321-8471 or visit us at 100 Casa Street, Suite D3, San Luis Obispo, CA 93405